NRG1 mutation
|
SCCHN
|
NRG1 mutation
|
SCCHN
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
NRG1 mutation
|
Pancreatic Cancer
|
NRG1 mutation
|
Pancreatic Cancer
|
afatinib + pertuzumab Sensitive: C3 – Early Trials
|
afatinib + pertuzumab Sensitive: C3 – Early Trials
|
NRG1 mutation
|
Pancreatic Cancer
|
NRG1 mutation
|
Pancreatic Cancer
|
erlotinib + pertuzumab Sensitive: C3 – Early Trials
|
erlotinib + pertuzumab Sensitive: C3 – Early Trials
|